Data from a multicenter placebo-controlled randomized trial of gamma inferon in patients with chronic granulomatous disease (CGD). 128 patients were randomized to either gamma inferon ($n=63$) or placebo ($n=65$). For each patient the times from study entry to initial and any recurrent serious infections are available. There is a minimum of one and a maximum of eight (recurrent) infection times per patient, with a total of 203 records.
data(cgd)